Sheldon Sloan
Insider
First SEC filing: June 3, 2026 · Latest: June 3, 2026
Insider at
Insider transactions
0 buys (P)
11 sells (S)
Net: $-7,354,471
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 1, 2026 | SYRE | M 10b5-1 | 8,334 | · | · | 305,000 Direct | -2.66% | Disposed | (price as of 2026-10-02) |
| July 1, 2026 | SYRE | S 10b5-1 | 1,834 | $88.34 | $162,016 | 0 Direct | -100.00% | Disposed | 5.5% (price as of 2026-10-02) |
| July 1, 2026 | SYRE | S 10b5-1 | 6,500 | $87.52 | $568,880 | 1,834 Direct | -77.99% | Disposed | 6.5% (price as of 2026-10-02) |
| July 1, 2026 | SYRE | M 10b5-1 | 8,334 | $27.46 | $228,852 | 8,334 Direct | · | Acquired | 239.4% (price as of 2026-10-02) |
| June 3, 2026 | SYRE | M 10b5-1 | 8,333 | · | · | 313,334 Direct | -2.59% | Disposed | (price as of 2026-10-02) |
| June 3, 2026 | SYRE | S 10b5-1 | 8,333 | $75.00 | $624,975 | 0 Direct | -100.00% | Disposed | 24.3% (price as of 2026-10-02) |
| June 3, 2026 | SYRE | M 10b5-1 | 8,333 | $27.46 | $228,824 | 8,333 Direct | · | Acquired | 239.4% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | M 10b5-1 | 78,333 | $27.46 | $2,151,024 | 78,333 Direct | · | Acquired | 239.4% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 21,306 | $69.53 | $1,481,406 | 57,027 Direct | -27.20% | Disposed | 34.0% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 19,656 | $70.61 | $1,387,910 | 37,371 Direct | -34.47% | Disposed | 32.0% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 8,777 | $71.56 | $628,082 | 28,594 Direct | -23.49% | Disposed | 30.2% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 12,777 | $72.94 | $931,954 | 15,817 Direct | -44.68% | Disposed | 27.8% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 10,358 | $73.74 | $763,799 | 5,459 Direct | -65.49% | Disposed | 26.4% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 5,059 | $74.60 | $377,401 | 400 Direct | -92.67% | Disposed | 24.9% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | S 10b5-1 | 400 | $75.37 | $30,148 | 0 Direct | -100.00% | Disposed | 23.6% (price as of 2026-10-02) |
| May 1, 2026 | SYRE | M 10b5-1 | 78,333 | · | · | 321,667 Direct | -19.58% | Disposed | (price as of 2026-10-02) |
| April 1, 2026 | SYRE | M 10b5-1 | 7,958 | $21.66 | $172,370 | 7,958 Direct | · | Acquired | 330.2% (price as of 2026-10-02) |
| April 1, 2026 | SYRE | S 10b5-1 | 7,958 | $50.00 | $397,900 | 0 Direct | -100.00% | Disposed | 86.4% (price as of 2026-10-02) |
| April 1, 2026 | SYRE | M 10b5-1 | 7,958 | · | · | 87,542 Direct | -8.33% | Disposed | (price as of 2026-10-02) |
| Jan. 9, 2026 | SYRE | A | 140,000 | · | · | 140,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 15, 2025 | SYRE | A | 95,500 | · | · | 95,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 1, 2024 | SYRE | A | 400,000 | · | · | 400,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 1, 2026 | SYRE | Stock Option (Right to Buy) | Common Stock | $27.46 | Oct. 1, 2034 | 8,334 | Disposed |
| June 3, 2026 | SYRE | Stock Option (Right to Buy) | Common Stock | $27.46 | Oct. 1, 2034 | 8,333 | Disposed |
| May 1, 2026 | SYRE | Stock Option (Right to Buy) | Common Stock | $27.46 | Oct. 1, 2034 | 78,333 | Disposed |
| April 1, 2026 | SYRE | Stock Option (Right to Buy) | Common Stock | $21.66 | Jan. 15, 2035 | 7,958 | Disposed |
| Jan. 9, 2026 | SYRE | Stock Option (Right to Buy) | Common Stock | $30.61 | Jan. 9, 2036 | 140,000 | Acquired |
| Jan. 15, 2025 | SYRE | Stock Option (Right to Buy) | Common Stock | $21.66 | Jan. 15, 2035 | 95,500 | Acquired |
| Oct. 1, 2024 | SYRE | Stock Option (Right to Buy) | Common Stock | $27.46 | Oct. 1, 2034 | 400,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $503,000 | · | · | · | $261,560 | · | $14,000 | $2,211,805 |
| 2024 | $124,000 | $120,000 | · | · | $59,500 | · | $9,760 | $9,388,740 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.